法国对皮肤美白注射产品发出禁令

2016-04-07 张雪飞 新华社

法国国家药品与健康产品安全局5日在其网站上发布决定,将禁止使用任何用于皮肤美白或提亮肤色的注射产品,并将禁止相关产品的生产、销售、无偿提供、进出口或广告宣传活动。该机构强调,此类产品的成分及使用方式可能对消费者的健康带来很大风险。如今,无论在法国还是其他国家,不少爱美人士、尤其是女性消费者愿意通过注射美白产品追求“完美”肤色。这些产品的生产厂家往往宣称,产品具有排毒养颜、使肌肤焕发年轻光彩的“神奇

法国国家药品与健康产品安全局5日在其网站上发布决定,将禁止使用任何用于皮肤美白或提亮肤色的注射产品,并将禁止相关产品的生产、销售、无偿提供、进出口或广告宣传活动。该机构强调,此类产品的成分及使用方式可能对消费者的健康带来很大风险。

如今,无论在法国还是其他国家,不少爱美人士、尤其是女性消费者愿意通过注射美白产品追求“完美”肤色。这些产品的生产厂家往往宣称,产品具有排毒养颜、使肌肤焕发年轻光彩的“神奇功效”,其主要成分包括谷胱甘肽、维生素C、表皮生长因子等。

法国国家药品与健康产品安全局指出,美白针等产品通常由静脉、肌肉或皮下注射,这种使用方式本身就存在很高风险。事实上,此类产品并未获得法国有关部门的上市批准,也缺少规范的质量和效益风险评估以确保其安全性。因此,目前各种形式的销售和宣传均违反现行法律法规。

据法国中毒防治中心统计,2015年,法国曾出现两例因使用美白注射产品产生不良反应的病例,其中一例患者出现恶心、头晕、心悸、腹部不适等一系列症状。

2015年9月,美国食品和药物管理局就曾发出警告称,皮肤美白注射产品不仅可能无效,还有可能给使用者带来感染肝炎、艾滋病等多种疾病的风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=78315, encodeId=1bede8315f9, content=也许总有, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78316, encodeId=9fbde83166c, content=会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399855, encodeId=fe2413998556c, content=<a href='/topic/show?id=51b56481e5c' target=_blank style='color:#2F92EE;'>#法国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64817, encryptionId=51b56481e5c, topicName=法国)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJAEDER5XgbF1YHYrZAUzQRb28zMfZSQYO9TlxMY9GrSlIvElouBEHntsqmbAWtxHwdqqtGx0dCsw/0, createdBy=ed132239308, createdName=neurowu, createdTime=Sat Apr 09 00:18:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76464, encodeId=ee1ce6464e4, content=欲速则不达, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 08 20:02:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76267, encodeId=6f67e62672f, content=爱美,还是走常规路线比较好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Thu Apr 07 13:57:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-14 李继凯

    也许总有

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=78315, encodeId=1bede8315f9, content=也许总有, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78316, encodeId=9fbde83166c, content=会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399855, encodeId=fe2413998556c, content=<a href='/topic/show?id=51b56481e5c' target=_blank style='color:#2F92EE;'>#法国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64817, encryptionId=51b56481e5c, topicName=法国)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJAEDER5XgbF1YHYrZAUzQRb28zMfZSQYO9TlxMY9GrSlIvElouBEHntsqmbAWtxHwdqqtGx0dCsw/0, createdBy=ed132239308, createdName=neurowu, createdTime=Sat Apr 09 00:18:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76464, encodeId=ee1ce6464e4, content=欲速则不达, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 08 20:02:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76267, encodeId=6f67e62672f, content=爱美,还是走常规路线比较好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Thu Apr 07 13:57:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-14 李继凯

    会有效果吗

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=78315, encodeId=1bede8315f9, content=也许总有, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78316, encodeId=9fbde83166c, content=会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399855, encodeId=fe2413998556c, content=<a href='/topic/show?id=51b56481e5c' target=_blank style='color:#2F92EE;'>#法国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64817, encryptionId=51b56481e5c, topicName=法国)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJAEDER5XgbF1YHYrZAUzQRb28zMfZSQYO9TlxMY9GrSlIvElouBEHntsqmbAWtxHwdqqtGx0dCsw/0, createdBy=ed132239308, createdName=neurowu, createdTime=Sat Apr 09 00:18:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76464, encodeId=ee1ce6464e4, content=欲速则不达, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 08 20:02:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76267, encodeId=6f67e62672f, content=爱美,还是走常规路线比较好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Thu Apr 07 13:57:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-09 neurowu
  4. [GetPortalCommentsPageByObjectIdResponse(id=78315, encodeId=1bede8315f9, content=也许总有, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78316, encodeId=9fbde83166c, content=会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399855, encodeId=fe2413998556c, content=<a href='/topic/show?id=51b56481e5c' target=_blank style='color:#2F92EE;'>#法国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64817, encryptionId=51b56481e5c, topicName=法国)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJAEDER5XgbF1YHYrZAUzQRb28zMfZSQYO9TlxMY9GrSlIvElouBEHntsqmbAWtxHwdqqtGx0dCsw/0, createdBy=ed132239308, createdName=neurowu, createdTime=Sat Apr 09 00:18:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76464, encodeId=ee1ce6464e4, content=欲速则不达, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 08 20:02:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76267, encodeId=6f67e62672f, content=爱美,还是走常规路线比较好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Thu Apr 07 13:57:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-08 1de3b290m83(暂无匿称)

    欲速则不达

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=78315, encodeId=1bede8315f9, content=也许总有, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78316, encodeId=9fbde83166c, content=会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:59:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399855, encodeId=fe2413998556c, content=<a href='/topic/show?id=51b56481e5c' target=_blank style='color:#2F92EE;'>#法国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64817, encryptionId=51b56481e5c, topicName=法国)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJAEDER5XgbF1YHYrZAUzQRb28zMfZSQYO9TlxMY9GrSlIvElouBEHntsqmbAWtxHwdqqtGx0dCsw/0, createdBy=ed132239308, createdName=neurowu, createdTime=Sat Apr 09 00:18:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76464, encodeId=ee1ce6464e4, content=欲速则不达, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Apr 08 20:02:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76267, encodeId=6f67e62672f, content=爱美,还是走常规路线比较好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160313/IMG56E50DEC424F44672.jpg, createdBy=ce5b1699635, createdName=Lisa971, createdTime=Thu Apr 07 13:57:00 CST 2016, time=2016-04-07, status=1, ipAttribution=)]
    2016-04-07 Lisa971

    爱美,还是走常规路线比较好。

    0

相关资讯

加快建立科学高效的药品审批体系

前不久,国务院发布《关于改革药品医疗器械审评审批制度的意见》(以下简称《意见》),《意见》紧紧围绕保障公众健康和促进产业转型升级这个大局,以提高药品质量为核心,以解决注册积压为重点,以鼓励创制新药为导向,提出了解决审评积压、提高药品质量的治本之策。这一药品监管史上的重大变革在业内引起广泛关注,业界期待这一新政能尽快落实,促使我国加快建立更加科学高效的药品审评审批体系。 近年来,随着我国经济的

政协委员对卫计委主任提了六个问题

导  语:国家卫计委认真贯彻落实2月17日国务院常务会议部署要求,在2016年全国“两会”即将召开之际,邀请部分全国人大代表、政协委员和民主党派人士召开座谈会,听取对推进健康中国建设、深化医药卫生体制改革和计划生育服务管理改革、统筹推进卫生计生事业发展的意见建议。温建民委员2月22曰在国家卫生计生委的发言“感谢李斌主任和卫计委的领导,请我来参加这一次的会议。我想讲几个问题。”第一:关

电子监管码制度不该因噎废食

日前,因不满国家食药监总局强制推行电子监管码,湖南养天和大药房企业集团有限公司一纸诉状将其告到北京一中院,请求确认国家食药监总局强制推行电子监管码的行政行为属于违法。对此,国家食药监总局宣布,暂停中国药品电子监管网,取消强制执行电子监管码扫码和数据上传的要求。此后,19家药品零售连锁企业又发布联合声明,以数据安全为由,建议全面取消现行药品电子监管码。 药品电子监管系统就是给药品最小包装附上一个电

生死劫,240个品种或将死掉!

1月23日,北京寒风刺骨。在这多年不遇的寒冬里,一场关于中国仿制药未来命运的思辨悄然开始。 由中国医药质量管理协会仿制药分会主办的“仿制药一致性评价机遇与挑战研讨会”将美国、日本仿制药评价的历程、方法、路径尽数披露于会上,并直指当下中国仿制药一致性评价遇到的问题。这对于开展仿制药一致性评价已经进入第四个年头的中国企业来说,无异于模糊与懵懂中见到一点星光和希望。 国家药典委秘书长张伟在研讨会

大量未经冷藏疫苗类产品流入多个省份 官方回应

食品药品监管总局已经责成山东省食品药品监管局会同公安和卫生计生部门,立即查清疫苗等相关产品的来源和流向,第一时间向社会公开相关信息。 澎湃新闻3月18日独家报道,山东省济南市公安机关破获一起法经营疫苗类产品案件,大量未经冷藏的疫苗类产品流入多个省份。国家食品药品监管总局官网18日晚就此发布消息称,总局新闻发言人表示,食品药品监管总局对此事件高度关注,已经责成山东省食品药品监管局会同公安和卫生计

我国暂停药品电子监管 拟建立药品追溯体系

国家食品药品监管总局20日就《药品经营质量管理规范》(修订草案)公开征求意见,拟将药品电子监管系统调整为药品追溯体系,取消强制执行电子监管码扫码和数据上传的要求。同时发布公告称,暂停执行药品电子监管的有关规定。 据介绍,由于现行有关药品经营企业执行药品电子监管的规定与国办日前印发的《关于加快推进重要产品追溯体系建设的意见》中落实企业追溯主体责任有关要求不符,有必要对现行《药品经营质量管理规范